Rice Hall James & Associates’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-2,228,059
| Closed | -$7.58M | – | 325 |
|
|
2018
Q3 | $7.58M | Sell |
2,228,059
-49,948
| -2% | -$180K | 0.27% | 103 |
|
|
2018
Q2 | $8.56M | Buy |
2,278,007
+361,533
| +19% | +$1.76M | 0.31% | 108 |
|
|
2018
Q1 | $7.84M | Buy |
1,916,474
+4,817
| +0.3% | +$22.4K | 0.31% | 98 |
|
|
2017
Q4 | $8.89M | Buy |
1,911,657
+310,485
| +19% | +$1.71M | 0.35% | 95 |
|
|
2017
Q3 | $11.4M | Sell |
1,601,172
-65,762
| -4% | -$473K | 0.5% | 81 |
|
|
2017
Q2 | $12.1M | Buy |
1,666,934
+326,285
| +24% | +$2.04M | 0.52% | 81 |
|
|
2017
Q1 | $8.26M | Buy |
1,340,649
+39,656
| +3% | +$217K | 0.4% | 91 |
|
|
2016
Q4 | $7.62M | Sell |
1,300,993
-24,924
| -2% | -$136K | 0.38% | 88 |
|
|
2016
Q3 | $7.04M | Buy |
1,325,917
+413,087
| +45% | +$2.23M | 0.37% | 92 |
|
|
2016
Q2 | $6.04M | Buy |
912,830
+11,767
| +1% | +$65.8K | 0.35% | 87 |
|
|
2016
Q1 | $4.21M | Buy |
901,063
+34,434
| +4% | +$137K | 0.24% | 91 |
|
|
2015
Q4 | $4.38M | Buy |
866,629
+350,340
| +68% | +$1.66M | 0.25% | 92 |
|
|
2015
Q3 | $1.82M | Buy |
516,289
+68,578
| +15% | +$459K | 0.12% | 175 |
|
|
2015
Q2 | $4.47M | Sell |
447,711
-43,276
| -9% | -$464K | 0.26% | 93 |
|
|
2015
Q1 | $6.25M | Buy |
490,987
+313,110
| +176% | +$4.03M | 0.36% | 80 |
|
|
2014
Q4 | $2.52M | Buy |
177,877
+59,008
| +50% | +$914K | 0.15% | 173 |
|
|
2014
Q3 | $1.63M | Buy |
+118,869
| New | +$1.82M | 0.11% | 209 |
|
Rice Hall James & Associates's KERX Position: Q4 2018 in Review
Rice Hall James & Associates sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 2,228,059 shares — an estimated $7.58M sold.
Rice Hall James & Associates first reported a position in KERX in Q3 2014 and held it in 17 quarters. The position peaked at $12.1M in Q2 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Rice Hall James & Associates reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Rice Hall James & Associates sold 2,228,059 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $7.58M.
- Rice Hall James & Associates first reported a position in Keryx Biopharmaceuticals Inc in Q3 2014 and held it in 17 quarters.
- Rice Hall James & Associates's Keryx Biopharmaceuticals Inc position peaked at $12.1M in Q2 2017.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Rice Hall James & Associates's 13F filing for Q4 2018, filed 14 Feb 2019.